Tae Man Kim

New Capabilities

As of May 2026: NOTE: Research indicates the CEO and founder of Alamar Biosciences is Yuling Luo, not Tae Man Kim. This entry may be in error and should be reviewed against primary sources.

Alamar Biosciences raised $191 million in its initial public offering on April 17, 2026 (nearly double the $100 million it originally planned) after investor demand exceeded available shares by more than tenfold. Shares priced at $17, opened at $22.60, and closed at $22.00, a 29% first-day gain that gave the company a market capitalization of roughly $1.53 billion. The Fremont, California company develops technology that detects proteins in blood at concentrations so low that conventional tests miss them entirely, potentially catching diseases years earlier than current methods allow. CEO and founder Yuling Luo told Reuters the company plans to use the proceeds to expand into cancer, cardiology, and other major disease areas. The company reported $74.2 million in revenue for fiscal year 2025 (nearly triple the year prior), creating a baseline for investors to measure future commercial growth.

Updated May 31